Cross-Regulation between Oncogenic BRAFV600E Kinase and the MST1 Pathway in Papillary Thyroid Carcinoma
2011

Interaction between BRAFV600E and MST1 in Papillary Thyroid Carcinoma

publication 10 minutes Evidence: moderate

Author Information

Author(s): Lee Seong Jin, Lee Min Hee, Kim Dong Wook, Lee SeongEun, Huang Songmei, Ryu Min Jeong, Kim Yong Kyung, Kim Sung Jin, Kim Soung Jung, Hwang Jung Hwan, Oh Sangphil, Cho Heeyeong, Kim Jin Man, Lim Dae-Sik, Jo Young Suk, Shong Minho

Primary Institution: Chungnam National University School of Medicine

Hypothesis

How does the BRAFV600E mutation interact with the MST1 pathway in papillary thyroid carcinoma?

Conclusion

The study found that BRAFV600E inhibits MST1 tumor suppressor pathways, affecting the behavior of papillary thyroid cancer.

Supporting Evidence

  • BRAFV600E mutation is found in 40-70% of papillary thyroid cancers.
  • RASSF1A is inactivated by hypermethylation in 20-32% of papillary thyroid cancers.
  • MST1 plays a crucial role in the induction of apoptosis through the RASSF1A-MST1-FoxO3 pathway.
  • Transgenic mice with BRAFV600E and MST1 knockout showed aggressive tumor phenotypes.

Takeaway

This study shows that a mutation in a gene called BRAFV600E can stop another protein, MST1, from doing its job, which helps cancer grow.

Methodology

The study used cell lines and transgenic mice to investigate the interaction between BRAFV600E and MST1.

Limitations

The study primarily focuses on in vitro and animal models, which may not fully represent human conditions.

Statistical Information

P-Value

p<0.001

Statistical Significance

p<0.05

Digital Object Identifier (DOI)

10.1371/journal.pone.0016180

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication